Publication | Closed Access

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

Week ResultsTreatment And PreventionAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyCombination TherapyAntiviral DrugHivMedicineDaily Dolutegravir